Skip to main content
Premium Trial:

Request an Annual Quote

Phylonix, Sanofi-Aventis Deutschland, and the University of Queensland Awarded US Patents

Premium
Phylonix has been awarded US Patent 7,435,870, “Methods of screening agents for activity using teleosts.”
 
Inventors listed on the patent are George Serbedzija, Carlos Semino, and Deanna Frost.
 
The patent provides methods of screening an agent for angiogenesis activity, toxic activity, and an effect on cell death activity in teleosts, according to its abstract.
 

 
Sanofi-Aventis Deutschland has been awarded US Patent 7,435,868, “Screening assay based on the forkhead transcription factor-dependent sod-3 promoter.”
 
Inventors listed on the patent are Edmund Hoppe, Ulrike Siebers, and Heike Schauerte.
 
The patent relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. As stated in the abstract, the patent provides transgenic Caenorhabditis elegans containing sod-3 reporter gene constructs, which are useful for, among other things, identifying genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are described that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.
 

 
The University of Queensland has been awarded US Patent 7,435,586, “Method of purification of cells.
 
Inventors listed on the patent are Perry Bartlett and Rodney Rietze.
 
According to its abstract, the patent generally relates to a method for generating a substantially homogeneous population of undifferentiated cells. In particular, the patent relates to purifying a substantially homogeneous population of neural stem cells and their progenitor or precursor cells. The patent is specifically directed to NSCs and precursor cells with the capacity to differentiate into cells and cell lineages required for developing, maintaining, or repairing the central nervous system in an animal such as a mammal.
 
The present invention is also directed to NSCs and progenitor and/or precursor cells which are capable of proliferation and differentiation into multiple cell lineages such as, but not limited to, neurons, oligodendrocytes, glia, and astrocytes.
 
The patent also presents the possibility of using NSCs and/or precursor cells for tissue regeneration or repair, including tissue associated with the central nervous system in animals, including a mammal. The NSCs of the present invention may be used to identify naturally occurring molecules such as cytokines, as well as molecules obtained from natural product screening or the screening of chemical libraries which induce proliferation of the NSCs.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.